Cargando…

Early oral antiviral use in patients hospitalised with COVID-19

Detalles Bibliográficos
Autores principales:	Zarębska-Michaluk, Dorota, Flisiak, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401972/ https://www.ncbi.nlm.nih.gov/pubmed/36029797 http://dx.doi.org/10.1016/S1473-3099(22)00522-9

Ejemplares similares

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough
por: Cao, Bin, et al.
Publicado: (2020)

Oral antiviral treatments for COVID-19: opportunities and challenges
por: Rahmah, Laila, et al.
Publicado: (2022)

Correction: Oral antiviral treatments for COVID-19: opportunities and challenges
por: Rahmah, Laila, et al.
Publicado: (2022)

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
por: Brzdęk, Michał, et al.
Publicado: (2023)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Ways to Eliminate Viral Hepatitis as a Global Health Threat
por: Flisiak, Robert, et al.
Publicado: (2022)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Monoclonals for patients hospitalised with COVID-19
por: Pogue, Jason M, et al.
Publicado: (2022)

Updates in Management of SARS-CoV-2 Infection
por: Flisiak, Robert, et al.
Publicado: (2022)

Convalescent plasma in patients hospitalised with COVID-19
por: Liu, Sean T H, et al.
Publicado: (2021)

Real-world effectiveness of oral antivirals for COVID-19
por: Burdet, Charles, et al.
Publicado: (2022)

Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
por: Matthay, Michael A, et al.
Publicado: (2020)

Renin-angiotensin system inhibitors in hospitalised patients with COVID-19
por: Williams, Bryan
Publicado: (2021)

COVID-19 and involuntary hospitalisation: navigating the challenge
por: Gold, Azgad, et al.
Publicado: (2020)

Baricitinib as the treatment of choice for hospitalised individuals with COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022)

Hospitalisation among vaccine breakthrough COVID-19 infections
por: Juthani, Prerak V, et al.
Publicado: (2021)

Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
por: Shapiro, Adrienne E, et al.
Publicado: (2022)

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19
por: So-Osman, Cynthia, et al.
Publicado: (2022)

Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2021)

COVID-19 outbreak and decreased hospitalisation of pregnant women in labour
por: Kumari, Vimla, et al.
Publicado: (2020)

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
por: Flisiak, Robert, et al.
Publicado: (2021)

Trends of infections and mortality due to hepatitis B virus (2005-2022) and the potential impact of the COVID-19 pandemic: a population-based study in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Obligation Is Not a Compulsion—The Quality of the Law and the Effectiveness and Safety of Vaccination against COVID-19
por: Kocańda, Kamila, et al.
Publicado: (2022)

Alternatives to conventional hospitalisation that enhance health systems' capacity to treat COVID-19
por: Nicolás, David, et al.
Publicado: (2021)

COVID-19: combining antiviral and anti-inflammatory treatments
por: Stebbing, Justin, et al.
Publicado: (2020)

Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
por: Flisiak, Robert, et al.
Publicado: (2023)

COVID-19 antivirals must not affect HIV drug supply
por: Barber, Melissa, et al.
Publicado: (2022)

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
por: Flisiak, Robert, et al.
Publicado: (2023)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
por: Møller Kirsebom, Freja Cordelia, et al.
Publicado: (2022)

Predicted COVID-19 positive cases, hospitalisations, and deaths associated with the Delta variant of concern, June–July, 2021
por: Shah, Syed Ahmar, et al.
Publicado: (2021)

Viral hepatitis C treatment shortening – what is the limit?
por: Zarębska-Michaluk, Dorota
Publicado: (2019)

Genotype 3-hepatitis C virus’ last line of defense
por: Zarębska-Michaluk, Dorota
Publicado: (2021)

Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

The incidence of Coronavirus disease 2019 (COVID-19) among vaccinated healthcare workers (HCWs): evidence for protection from hospitalisation from an Indonesian cohort
por: Kozlakidis, Zisis
Publicado: (2023)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

The use of inhaled corticosteroids in early-stage COVID-19
por: Mangin, Dee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9si2fe766e0veqra97gg6j6ufr